hotspot -WSS

hotspot

author：leisure time 2025-08-25 07:28:33 - browse：229

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

WSS

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Federal judge rules Oregon’s tough new gun law is constitutional

Blood tests recalled over risk of missed heart attack diagnosis

AltruBio raises $225 million to develop ulcerative colitis drug

AltruBio raises $225 million to develop ulcerative colitis drug

BIO to announce reorganization, senior leaders expected to depart

focus

hotspot

Gilead needs Arcellx more than ever

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

Novel spinal cord stimulator treats paralysis without surgery

Duchenne breakthrough therapy leaves behind pioneering families

The effects of a landmark ruling on DNA ownership are becoming clearer

How to save PrEP access — and even expand it

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

As demand for Covid shots wanes, Moderna seeks its next success

J&J expands global access to TB drug amid advocacy campaign

Psychedelics group wrestles with new pharma identity

Who gets to use the title 'doctor'?

hotspot

Congress likely to miss an opportunity to fix drug shortages issue

Congress: Eradicate hepatitis C and reduce the deficit

J&J expands global access to TB drug amid advocacy campaign

Grail faces three suits alleging harassment, retaliation

As health system earnings go up, health insurance stocks go down

Has Bernie Sanders reached the limit of his pharma bullying effort?

knowledge

Wikipedia

focus

explore